425: Endo, Inc. Reports Q1 2025 Results, Reaffirms Full-Year Guidance Amidst Merger Plans

Endo, Inc. announces its Q1 2025 financial results, highlighting revenue of $393 million and adjusted EBITDA of $99 million, while reaffirming its full-year financial guidance and progressing with its merger with Mallinckrodt.

Summary

• Endo, Inc. reported first quarter 2025 revenues of $393 million and adjusted EBITDA of $99 million.
• The company is reaffirming its full-year 2025 financial guidance, expecting revenues between $1.78 billion and $1.86 billion and adjusted EBITDA between $620 million and $650 million.
• XIAFLEX revenues grew 7 percent compared to the first quarter of 2024, driven by growth in both Peyronie's disease and Dupuytren's contracture indications.
• Sterile Injectables revenues were $71 million, impacted by competitive pressure on VASOSTRICT and ADRENALIN vials, but the company is seeing strong customer adoption of the ADRENALIN RTU bag.
• The company completed three new FDA submissions for its Sterile Injectables pipeline in the first quarter and is on track to achieve its goal of seven submissions and three product launches in 2025.
• The merger with Mallinckrodt is expected to close in the second half of the year, and the divestiture of the International Pharmaceuticals business is expected to close in mid-2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there are some challenges and competitive pressures, the company is reaffirming guidance, making progress on its pipeline, and moving forward with strategic transactions.

Positives

• XIAFLEX continues to be a strong growth driver, with revenues up 7% year-over-year.
• The company is making progress in its Sterile Injectables pipeline, with three FDA submissions in Q1 and a goal of seven submissions and three launches for the year.
• The ADRENALIN RTU bag is experiencing strong customer adoption, which is expected to offset competitive pressure on ADRENALIN vials in the second half of 2025.
• The merger with Mallinckrodt and the divestiture of the International Pharmaceuticals business are both on track.
• Lidocaine patch revenues increased 16 percent compared to prior year as we continue to provide the market with reliable supply.

Negatives

• Sterile Injectables revenues decreased due to competitive pressure on VASOSTRICT and ADRENALIN vials.
• Generic Pharmaceuticals segment revenues decreased slightly due to competitive pressure across a number of products.
• First quarter 2025 adjusted EBITDA was $99 million compared to $146 million in the first quarter 2024.
• First quarter 2025 adjusted net income was $24 million compared to $131 million in the first quarter 2024.

Risks

• Continued competitive pressure in the Sterile Injectables and Generic Pharmaceuticals segments could impact future revenues.
• The merger with Mallinckrodt and the divestiture of the International Pharmaceuticals business are subject to regulatory approvals and other closing conditions.
• Potential tariff exposure, particularly on imports from India, could impact the Generic segment.
• The company's net debt-to-adjusted EBITDA ratio is approximately 3.6 times.

Future Outlook

Endo reaffirms its full-year 2025 financial guidance and expects the merger with Mallinckrodt and the divestiture of the International Pharmaceuticals business to close in the second half and mid-2025, respectively. The company anticipates higher revenues and adjusted EBITDA in the second half of 2025, driven by XIAFLEX and recently launched sterile products.

Management Comments

• Scott Hirsch: 'I am pleased that Endo had a good start to the year, with all segments of the business performing in line with our expectations.'
• Scott Hirsch: 'These transactions provide meaningful transformation to the Company and are expected to enhance the combined growth potential and value creation.'
• Mark Bradley: 'We expect adjusted EBITDA to be lower and our net debt-to-adjusted EBITDA ratio to be higher in the first half of 2025 compared to the second half of 2025.'
• Scott Hirsch: 'We are actively working toward the merger with Mallinckrodt to create a global, scaled, diversified pharmaceutical industry leader.'

Industry Context

Endo's focus on sterile injectables and branded pharmaceuticals aligns with industry trends towards specialized and high-value products. The merger with Mallinckrodt aims to create a larger, more diversified player in the pharmaceutical market, potentially increasing competitiveness and market share.

Comparison to Industry Standards

• Comparing Endo's performance to companies like Teva Pharmaceuticals and Viatris, which also have significant generic and specialty pharmaceutical businesses, Endo's revenue and EBITDA figures provide a benchmark for assessing its operational efficiency and market positioning.
• The 7% growth in XIAFLEX revenues can be compared to the growth rates of similar specialty drugs in the dermatology and urology fields to gauge its market penetration and acceptance.
• Endo's investment in sterile injectable pipeline and its goal of 7 FDA submissions and 3 product launches in 2025 can be benchmarked against companies like Hikma Pharmaceuticals and Amphastar Pharmaceuticals, which are also focused on developing and launching sterile injectable products.

Stakeholder Impact

• Shareholders: The merger with Mallinckrodt is expected to enhance value creation.
• Customers: The company is focused on improving the patient and provider experience, particularly with XIAFLEX.
• Employees: The company is undergoing significant transformation, which may impact job roles and responsibilities.
• Hospitals: The company is investing in its Sterile Injectables pipeline to meet the needs of hospitals.

Next Steps

• Continue working towards closing the merger with Mallinckrodt in the second half of 2025.
• Complete the divestiture of the International Pharmaceuticals business in mid-2025.
• Advance the Sterile Injectables pipeline with the goal of seven FDA submissions and three product launches in 2025.
• Report top-line Plantar Fibromatosis PFI results around year-end.
• Initiate development activities across three new indications: hammer toe, urethral stricture, and arthrofibrosis of the knee post-knee arthroplasty.

Key Dates

Keywords

Endo, Mallinckrodt, XIAFLEX, Sterile Injectables, Generics, Merger, Divestiture, Financial Results, EBITDA, Revenues